Alexion Pharma Canada Concludes LOI With Pan-Canadian Pharmaceutical Alliance For Ultomiris

(RTTNews) - Alexion Pharma Canada Corp. (AZN), AstraZeneca's Rare Disease group, Tuesday said it has entered into a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for Ultomiris for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) and to treat adult and pediatric patients with atypical hemolytic uremic syndrome (aHUS).

The LOI with the pCPA enables individual provinces and territories to list Ultomiris on their formularies.

PNH is a progressive blood disorder characterized by red blood cell destruction within blood vessels resulting in thrombosis.

atypical hemolytic uremic syndrome is a disease that causes blood clots in small blood vessels.

Ultomiris is approved in the US, EU and Japan for the treatment of certain adults with generalised myasthenia gravis, paroxysmal nocturnal haemoglobinuria (PNH), for certain children with PNH in the US and EU, and for certain adults and children with atypical haemolytic uraemic syndrome. Further, Ultomiris is approved in the EU and Japan for the treatment of certain adults with neuromyelitis optica spectrum disorder (NMOSD).